Trial · NCT06723171
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
NCT06723171, Phase 2, Suspended, Io Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis. Trials, record NCT06723171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06723171
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
- NCT number
- NCT06723171
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Io Therapeutics
- Conditions
- Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
- Interventions
- IRX4204, Placebo
- First posted
- 2024-12-09
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo | Baseline (Day 1) to Day 42 | Percentage of participants achieving an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at Day 28 with at least a 2-grade improvement from Baseline to end of study. |
| Secondary | To evaluate if participants receiving IRX4204 have greater improvement in participant reported outcomes when compared to participants receiving placebo | from Baseline (Day 1) to Day 28 | Change in Daily Quality of Life Index (DLQI) score will be evaluated. The DLQI is calculated by adding the score of each question, resulting in a minimum of 0 to a maximum of 30. The higher the score, the more quality of life is impaired. |
| Secondary | To evaluate if participants receiving IRX4204 experience a greater reduction in affected Body Surface Area when compared to participants receiving placebo | from Baseline (Day 1) to Day 28 | Percent change in affected Body Surface Area (BSA) from Baseline to end of treatment will be evaluated. The body surface area refers to the total amount of skin on the body that is covered by psoriasis lesions and used to assess the severity of the condition. A higher percentage indicates a more severe case of psoriasis. |
| Secondary | To evaluate if a greater proportion of participants receiving IRX4204 achieve PASI50, PASI75 and PASI90 when compared to participants receiving placebo | from Baseline (Day 1) to End of Study (Day 42) | Proportion of participants to achieve PASI50 (50% or greater improvement from Baseline), PASI75, and PASI90 to the end of the study will be evaluated. Achieving PASI 50, PASI 75, and PASI 90 indicates different levels of improvement in psoriasis severity as measured by the Psoriasis Area and Severity Index (PASI) score, with PASI 50 indicating a 50% reduction from baseline, PASI 75 signifying a 75% reduction, and PASI 90 representing a 90% reduction in psoriasis symptoms. Higher PASI numbers signifying increasingly clearer skin. |
| Secondary | To evaluate if participants receiving IRX4204 achieve greater improvement from baseline in disease and symptom severity as measured by the Psoriasis Area and Severity Index (PASI). | from Baseline (Day 1) to End of Treatment (Day 28) | Change From Baseline to Day 28 in mean Psoriasis Area and Severity Index (PASI) score of participants receiving IRX4204 compared to placebo. |
| Other | Incidence of Treatment Emergent and Serious Adverse Events | from Baseline (Day 1) to End of Study (Day 42) | The number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and the number of participants who experienced TEAEs and SAEs will also be tabulated to evaluate the safety profile of IRX4204. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06723171
GET https://conductscience.org/api/trials/v1/NCT06723171/registered